Navigation Links
Rules-Based Medicine, Inc. Launches Human Kidney Damage Biomarker Panel
Date:1/15/2009

Complements the RBM Rat Kidney Panel developed in conjunction with the Critical Path Initiative

AUSTIN, Texas, Jan. 15 /PRNewswire/ -- Rules-Based Medicine, Inc. (RBM), the world's leading multiplexed biomarker testing laboratory, today announced the launch of its Human Kidney Multi-Analyte Profile (MAP), a cost-effective biomarker testing service designed to aid pharmaceutical and biotechnology companies in their efforts to improve drug development through better understanding of drug toxicity. The Human Kidney MAP will be used in clinical trials to reveal early signs and locations of drug-induced kidney damage, known as renal toxicity or nephrotoxicity, thereby guiding important decisions on lead compounds and dosage.

"The Human Kidney MAP is an important response to the FDA's Critical Path Initiative, which highlighted the need for new tools to better understand the safety profile of new drugs," said Craig Benson, RBM president and chief executive officer. "By providing a quantitative and predictive multiplexed biomarker test for renal toxicity, we will help our customers improve safety, mitigate risk, and reduce costs associated with drug development."

RBM's Human Kidney MAP utilizes a multiplexed panel of 16 biomarkers to detect early renal damage and pinpoint the location within the kidney. Both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) recently decided to accept data related to certain biomarkers of kidney damage as part of the drug approval process in conjunction with new safety initiatives. Historically, regulatory agencies have required drug companies to provide results of blood urea nitrogen (BUN) and serum creatinine tests as indicators of kidney damage. Studies, however, suggest these tests detect only late signs of kidney damage and provide no information on the location of damage.

The Human Kidney MAP was developed using a translational medicine approach. In 2008, RBM commercialized a Rat Kidney MAP based on an ambitious study funded by the FDA's Critical Path Initiative through the Predictive Safety Testing Consortium. The Human Kidney MAP contains many of the same biomarkers and is designed to detect general signs of kidney damage. Drugs in circulation are concentrated up to 1000-fold in the kidney compared to plasma, magnifying the potential for renal toxicity of any drug.

Kidney damage also occurs in connection with diseases such as diabetes, hypertension, and autoimmune conditions, among others. RBM has established and is seeking additional collaborations with leading academic and pharmaceutical researchers to develop diagnostic applications based on the Human Kidney MAP.

About Rules-Based Medicine

Rules-Based Medicine (RBM) provides comprehensive protein biomarker products and services centered on its Multi-Analyte Profiling (MAP) technology. Its service platform (RodentMAP(R) and HumanMAP(R)) provides pre-clinical and clinical researchers with reproducible, quantitative, multiplexed immunoassay data for hundreds of proteins cost-effectively in multiple species, and from a small sample volume. The Company also offers innovative and proprietary ex vivo testing systems such as TruCulture(TM), the first fully-closed, reproducible whole blood culture system. RBM is actively developing multiplexed diagnostic tests to detect the presence of complex diseases and conditions in areas of unmet medical need such as neuropsychiatry, nephrology, immunology and cardiology. More information about RBM is located at www.rbmmaps.com.

RodentMAP(R) and HumanMAP(R) are registered trademarks of Rules-Based Medicine Inc.


'/>"/>
SOURCE Rules-Based Medicine, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Luminex Corporation Reaches Settlement With Rules Based Medicine, Inc.
2. Chemical Engineering Conference Highlights Energy, Biomedicine, Pharmaceuticals, Sustainability and Centennial
3. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
4. Novozymes Launches Enzyme to Reduce Acrylamide in Food
5. Enova Medical Launches Exos Corporation
6. Elekta Launches New Linear Accelerator at 2007 ESTRO to Expand Cancer Treatment Availability
7. Signalifes Dr. Harmison Launches Award-Winning Ambulatory Heart Monitor
8. ThirdBiotech Networking Group Launches
9. BioReliance Launches Next-Generation Genotoxicity Screening Service
10. Midwest Research Institute Launches Center for Biological Safety and Security (CBS2)
11. BioReliance Corporation Launches iNet(TM) for Online Results Tracking of Biological Safety Tests
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... April 26, 2017 , ... WonderWorks, ... NASA to showcase the future of deep space exploration and inspire space enthusiasts. ... Orion spacecraft and includes a guest appearance by former Shuttle Astronaut Don Thomas. ...
(Date:4/26/2017)... (PRWEB) , ... April 26, 2017 , ... ... headlines and drive high-level conversations among healthcare industry stakeholders, the discussion surrounding the ... – taking place May 15-18, 2017 in Los Angeles, Calif. Hosted by the ...
(Date:4/25/2017)... April 25, 2017 Providence ... licensed its novel immune-modulating technology to an undisclosed global ... allergy. Tregitopes, pronounced T·rej·itopes, are a ... by EpiVax CEO Annie De Groot ... immunoglobulin G, an autoimmune disease therapy, Tregitopes are ...
(Date:4/24/2017)... NEW YORK , April 24, 2017  Dante Labs ... interpretation at only EUR 850 (ca. $900). While American individuals ... marks the first time Europeans can access WGS below EUR ... which are crucial to leveraging genetic information to make informed ... more. ...
Breaking Biology Technology:
(Date:4/3/2017)... April 3, 2017  Data captured by ... platform, detected a statistically significant association between ... to treatment and objective response of cancer ... to predict whether cancer patients will respond ... as well as to improve both pre-infusion potency ...
(Date:3/29/2017)... March 29, 2017  higi, the health IT company ... North America , today announced a Series ... acquisition of EveryMove. The new investment and acquisition accelerates ... tools to transform population health activities through the collection ... higi collects and secures data today on ...
(Date:3/24/2017)... -- Research and Markets has announced the addition of ... - Industry Forecast to 2025" report to their offering. ... The Global Biometric Vehicle ... around 15.1% over the next decade to reach approximately $1,580 million ... estimates and forecasts for all the given segments on global as ...
Breaking Biology News(10 mins):